Adaptimmune Therapeutics PLC Annual Operating Income (Loss) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2023.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the quarter ending June 30, 2024 was $68.7M.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the twelve months ending June 30, 2024 was -$77.1M, a 32.1% increase year-over-year.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2023 was -$140M, a 14.8% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2022 was -$164M, a 1.06% decline from 2021.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2021 was -$162M, a 21.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$140M +$24.2M +14.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 -$164M -$1.72M -1.06% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 -$162M -$28.8M -21.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 -$133M +$6.37M +4.55% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-06
2019 -$140M -$57.4M -69.7% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-14
2018 -$82.4M -$1.7M -2.11% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$80.7M -$7.86M -10.8% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-27
2016 -$72.8M -$48.2M -195% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$24.6M -$13.1M -114% Jul 1, 2014 Jun 30, 2015 10-K 2018-03-15
2014 -$11.5M -$2.77M -31.7% Jul 1, 2013 Jun 30, 2014 10-K 2017-03-13
2013 -$8.75M Jul 1, 2012 Jun 30, 2013 8-K 2016-07-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.